VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma

VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma Brian I. Rini Oncologist 2005; 10: 191-197 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the biology underlying clear cell RCC, including inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression. Describe the mechanisms by which agents currently undergoing clinical testing in metastatic RCC inhibit VEGF. Describe the preliminary clinical results seen with VEGF inhibition in metastatic RCC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 25, 2005 Most Recent Review: Mar. 25, 2005* Most Recent Update: Mar. 25, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.